Pulmonary blastoma: An NCDB analysis of demographic and socioeconomic factors. The characteristics and treatments across four groups.

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.

New Specialized Care for West Hollywood, Beverly Hills, and Hollywood Residents Facing Treatment-Resistant Depression ...

Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...